Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID

Mar 19, 2024

TORONTO, March 19, 2024 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced...

PharmaDrug’s SecureDose Announces Filing of US Provisional Patent for Manufacturing Method for Biosynthetic Pharmaceutical Grade Cocaine

Mar 13, 2024

Toronto, Ontario – March 13, 2024 – PharmaDrug Inc. (CSE: PHRX) (OTC PINK: LMLLF) (“PharmaDrug” or the “Company”), a specialty pharmaceutical company focused on the research, development and commercialization of...

PharmaDrug Appoints Current Board Member Dr. David Kideckel as Chairman

Feb 27, 2024

Toronto, Ontario – February 27, 2024 – PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (“PharmaDrug” or the “Company”), a specialty pharmaceutical company focused on the research, development and commercialization of...

PharmaDrug’s Sairiyo Successfully Demonstrates Ability to Manufacture Cepharanthine (PD-001) for Human Clinical Studies

Feb 14, 2024

Company to pursue regulatory filing for Phase I/II clinical study   Toronto, Ontario – February 14, 2024 – PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (“PharmaDrug” or the “Company”), a specialty pharmaceutical company...

Revive Therapeutics Explores the Use of Bucillamine for Long COVID

Feb 1, 2024

TORONTO, Feb. 01, 2024 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced...